Literature DB >> 16868020

Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test.

M H Buch1, C P Denton, D E Furst, L Guillevin, L J Rubin, A U Wells, M Matucci-Cerinic, G Riemekasten, P Emery, H Chadha-Boreham, P Charef, S Roux, C M Black, J R Seibold.   

Abstract

BACKGROUND: The 6-min walk test (6MWT) is increasingly used as an outcome measure in interstitial lung disease (ILD). AIM: To evaluate the usefulness of the 6MWT in a cohort of patients with ILD secondary to systemic sclerosis (SSc) and to correlate with established physiological parameters.
METHODS: 163 patients with SSc-ILD were recruited for a multicentre, randomised, double-blind clinical trial. Available data at protocol screening included repeated 6MWTs, pulmonary function testing with diffusing capacity, Doppler echocardiography and high-resolution computed tomography of the thorax. Borg Dyspnoea Index was evaluated before and after 6MWT.
RESULTS: Mean (standard deviation (SD)) distance walked during walk test 1 was 396.6 (84.55) m compared with 399.5 (86.28) m at walk test 2. The within-subject, intertest correlation as determined by Pearson's correlation coefficient testing was 0.95 (p<0.001). However, only weak correlations of 6MWT with percentage forced vital capacity and the Borg Dyspnoea Index were observed, and no correlation was observed with percentage diffusing capacity.
CONCLUSION: These data confirm the high reproducibility of the 6MWT in patients with SSc-ILD and therefore the validity of the test in this cohort. The lack of correlation of 6MWT with standard physiological parameters of ILD suggests a multifactorial basis for limited exercise capacity in patients with SSc and calls into question the utility of the 6MWT as a measure of outcome in future studies on SSc-ILD.

Entities:  

Mesh:

Year:  2006        PMID: 16868020      PMCID: PMC1798506          DOI: 10.1136/ard.2006.054866

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  25 in total

1.  Echocardiographic alterations in systemic sclerosis: a longitudinal study.

Authors:  Stefania Maione; Giovanna Cuomo; Anna Giunta; Laura Tanturri de Horatio; Giovanni La Montagna; Francesco Manguso; Ivo Alagia; Gabriele Valentini
Journal:  Semin Arthritis Rheum       Date:  2005-04       Impact factor: 5.532

2.  Cyclophosphamide versus placebo in scleroderma lung disease.

Authors:  Donald P Tashkin; Robert Elashoff; Philip J Clements; Jonathan Goldin; Michael D Roth; Daniel E Furst; Edgar Arriola; Richard Silver; Charlie Strange; Marcy Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean E Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fredrick Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky
Journal:  N Engl J Med       Date:  2006-06-22       Impact factor: 91.245

3.  American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique--1995 update.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1995-12       Impact factor: 21.405

4.  Standardization of Spirometry, 1994 Update. American Thoracic Society.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1995-09       Impact factor: 21.405

5.  Non-invasive assessment of left ventricular diastolic function in patients with systemic sclerosis.

Authors:  E Kazzam; A Waldenström; J Landelius; R Hällgren; A Arvidsson; K Caidahl
Journal:  J Intern Med       Date:  1990-08       Impact factor: 8.989

6.  Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia.

Authors:  Tam Eaton; Pam Young; David Milne; Athol U Wells
Journal:  Am J Respir Crit Care Med       Date:  2005-01-07       Impact factor: 21.405

7.  Disturbed right ventricular diastolic function in patients with systemic sclerosis: a Doppler tissue imaging study.

Authors:  Per Lindqvist; Kenneth Caidahl; Grete Neuman-Andersen; Cecilia Ozolins; Solbritt Rantapää-Dahlqvist; Anders Waldenström; Elsadig Kazzam
Journal:  Chest       Date:  2005-08       Impact factor: 9.410

8.  A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnoea during exercise.

Authors:  R C Wilson; P W Jones
Journal:  Clin Sci (Lond)       Date:  1989-03       Impact factor: 6.124

9.  Severe restrictive lung disease in systemic sclerosis.

Authors:  V D Steen; C Conte; G R Owens; T A Medsger
Journal:  Arthritis Rheum       Date:  1994-09

10.  Comparison of echocardiographic assessment of cardiac hemodynamics in the intensive care unit with right-sided cardiac catheterization.

Authors:  S F Dabaghi; R Rokey; J M Rivera; W I Saliba; P A Majid
Journal:  Am J Cardiol       Date:  1995-08-15       Impact factor: 2.778

View more
  25 in total

Review 1.  Interstitial lung disease in scleroderma.

Authors:  Sara R Schoenfeld; Flavia V Castelino
Journal:  Rheum Dis Clin North Am       Date:  2015-02-26       Impact factor: 2.670

2.  Development of a provisional core set of response measures for clinical trials of systemic sclerosis.

Authors:  D Khanna; D J Lovell; E Giannini; P J Clements; P A Merkel; J R Seibold; M Matucci-Cerinic; C P Denton; M D Mayes; V D Steen; J Varga; D E Furst
Journal:  Ann Rheum Dis       Date:  2007-09-24       Impact factor: 19.103

3.  Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design.

Authors:  Dinesh Khanna; James R Seibold; Athol Wells; Oliver Distler; Yannick Allanore; Chris Denton; Daniel E Furst
Journal:  Curr Rheumatol Rev       Date:  2010-05-01

4.  Outcome Measures for Clinical Trials in Interstitial Lung Diseases.

Authors:  Matthew R Lammi; Robert P Baughman; Surinder S Birring; Anne-Marie Russell; Jay H Ryu; Marybeth Scholand; Oliver Distler; Daphne LeSage; Catherine Sarver; Katerina Antoniou; Kristin B Highland; Otylia Kowal-Bielecka; Joseph A Lasky; Athol U Wells; Lesley Ann Saketkoo
Journal:  Curr Respir Med Rev       Date:  2015

Review 5.  Scleroderma lung: pathogenesis, evaluation and current therapy.

Authors:  Jacob M van Laar; Jan Stolk; Alan Tyndall
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  [Medico-legal assessment of systemic sclerosis].

Authors:  M Graninger
Journal:  Z Rheumatol       Date:  2007-10       Impact factor: 1.372

Review 7.  [Risk of infection by biologics].

Authors:  J U Holle; S Schinke; W L Gross
Journal:  Z Rheumatol       Date:  2008-07       Impact factor: 1.372

Review 8.  Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials.

Authors:  Marc Humbert; Manjit Singh; Daniel E Furst; Dinesh Khanna; James R Seibold
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

Review 9.  Interstitial lung disease points to consider for clinical trials in systemic sclerosis.

Authors:  Dinesh Khanna; James Seibold; Jonathan Goldin; Donald P Tashkin; Daniel E Furst; Athol Wells
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

Review 10.  Systemic sclerosis-associated pulmonary arterial hypertension.

Authors:  Neal F Chaisson; Paul M Hassoun
Journal:  Chest       Date:  2013-10       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.